Elli Roberts, PA
Medical · Shawnee Mission, KSNPI 1578953162
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 442 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 16.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,641 and has fallen 54.1% since, to $1,211 in 2025. Among medical clinicians in KS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 442 payments — averaging $18.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Novo Nordisk$1K
- Abbott$781
- Bayer$639
- Corcept Therapeutics$632
- Radius Health, Inc.$431
- plus $3K from 25 others
What the payments were for
- Food & beverage$8,321100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 69 | $1,395 |
| Novo Nordisk | 66 | $1,100 |
| Abbott | 64 | $781 |
| Bayer | 30 | $639 |
| Corcept Therapeutics | 31 | $632 |
| Radius Health, Inc. | 18 | $431 |
| Boehringer Ingelheim | 25 | $425 |
| AstraZeneca(2 entities) | 17 | $384 |
| Tandem Diabetes Care, Inc. | 8 | $283 |
| Amneal Pharmaceuticals LLC | 16 | $280 |
| AbbVie | 15 | $248 |
| Ascensia Diabetes Care US Inc. | 12 | $230 |
| Novartis | 12 | $210 |
| Dexcom, Inc. | 6 | $199 |
| Mannkind Corporation | 8 | $163 |
| Sanofi-aventis U.S. LLC | 7 | $141 |
| Cequr Corporation | 2 | $141 |
| Recordati_rare_diseases_inc. | 6 | $127 |
| Amgen | 6 | $103 |
| Merck | 5 | $81 |
| Xeris Pharmaceuticals, Inc. | 5 | $78 |
| IBSA Pharma Inc. | 4 | $68 |
| Medtronic | 2 | $29 |
| Ascendis Pharma Endocrinology Inc | 1 | $28 |
| Amarin Pharma, Inc. | 1 | $24 |
| Sequel Med Tech, LLC | 1 | $23 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Eisai Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,321 in reported general payments places this provider in the 90th percentile of 205 medical providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 222 | $292,884 |
| JardianceEmpagliflozin | 156 | $159,006 |
| MounjaroTirzepatide | 85 | $108,946 |
| TrulicityDulaglutide | 47 | $79,401 |
| Tresiba Flextouch U-200Insulin Degludec | 26 | $46,545 |
| FarxigaDapagliflozin Propanediol | 28 | $32,550 |
| Tresiba Flextouch U-100Insulin Degludec | 38 | $27,704 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 121 | $19,843 |
| RybelsusSemaglutide | 12 | $19,106 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 16 | $17,812 |
| Novolog FlexpenInsulin Aspart | 55 | $15,331 |
| Humalog Kwikpen U-100Insulin Lispro | 57 | $15,199 |
| KerendiaFinerenone | 12 | $14,289 |
| JanuviaSitagliptin Phosphate | 22 | $13,987 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 28 | $13,106 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,100 | $311,991234 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,395 | $188,347132 claims |
| Boehringer IngelheimJardiance | $425 | $159,006156 claims |
| AstraZenecaFarxiga | $384 | $32,55028 claims |
| BayerKerendia | $639 | $14,28912 claims |
| MerckJanuvia | $81 | $13,98722 claims |
| AbbVieSynthroid | $248 | $7,18767 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $280 | $1,634161 claims |
| Sanofi-aventis U.S. LLCLantus | $141 | $1,42111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 205 medical providers in Kansas.
Other medical in Shawnee Mission
- Nicole BergeShawnee Mission$10K
- Linly StevensOverland Park$111K
- Shana ArnholdShawnee$82K
- Richard AllenbachWichita$70K
- Laura LudlowTopeka$61K
- Anita KishOlathe$58K
- Kathryn WelchWichita$32K
- Courtney SteneOverland Park$22K
- Janella DewittOverland Park$19K
- Walter DeanMission$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.